Member Info for Serendipidity

How do you filter someone? Would also like to hide this annoying child

Wow this stock is illiquid, had to buy at 22.4 to get a fill and it moved the price, ah well only an extra £100 cost, looking forward to this doing well

And I lost £70k on those NMC fraudsters!

Interesting debate about shorting. They are unpopular here as unfortunately LSE has a lot of rampers who shout down any negativity and blame MMS/shorters for any bad news.
IMO they add efficiency and stop a share being over inflated, it was the only social benefit of hedge funds who operate in a zero sum market and often win against each other or, worse, pension funds and LT investors (and stupid chancellors like Lamont and Brown).
Arguably shorting on loaned stock is no worse than me buying stock on margin

I’m out at 0.42, painful as down 30% but only myself to blame due to insufficient research.

The concept is interesting and might well work but a board of 1 plus two NEDs is poor governance and a potential revenue stream of roughly 7m plus - other 2 in March doesn’t justify a MC of 138m.

GL to those who are still in

Edited to add:

Reading GB tweets Dell will provide “data services” whatever that means. This company needs funding, logistics and marketing.

He really should less time on Twitter ramping his company and more talking to business analysts to figure out how the company markets its products and gets to mass production of detection and scanners ASAP, and has some big orders to announce

If the share price had gone up it would have been because the AGM had effectively run and had announced something positive that would have increased the SP. And we would all be happy.

No one is crying, we are having an adult conversation. I got out at 65 and would like to buy back in as there is a good product there. The fact I am not buying hugely at 30p is because I now have huge doubts about the boards grasp of business rather than just science.

Thanks muggins, you are in danger of starting an intelligent debate on LSE. Unfortunately you will get shouted down by the usual fanboy idiots.

SKIN are in a race to get their product developed and marketed before vaccines or similar products (eg Biobot) beat them to it. Yes it has used above and beyond COVID but that is where the big immediate value is. Many good products have failed as they didn’t come to market quickly enough. Dell is a good partner but the significance was poorly explained. GB can claim it’s not pharma but announcing a partnership with Roche or GSK would have propelled this to next level. They can fast track production and open doors to governments.

Well balance post Col13

A great morning RNS but an amateur AGM with poor structure and lack of clarity. GB ramped his own company promising exciting news and it wasn’t. Dell wasn’t exciting or explained properly, SKIN don’t need a logistic s partner they need a big pharma to JV with that can properly market their great products and get in front of governments and big corporates.

I was lucky and got out at 65 at 8am, looking for get back in around 30